GRI Bio Revenue and Competitors
Estimated Revenue & Valuation
- GRI Bio's estimated annual revenue is currently $2.3M per year.
- GRI Bio's estimated revenue per employee is $155,000
Employee Data
- GRI Bio has 15 Employees.
- GRI Bio grew their employee count by 25% last year.
GRI Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
GRI Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is GRI Bio?
GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI’s Natural Killer T (NKT) cell-based therapies are being developed for liver disease and acute liver failure. NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.3M | 15 | -17% | N/A |
#2 | $0.5M | 15 | 0% | $16M |
#3 | $2.1M | 15 | -21% | N/A |
#4 | $1.3M | 15 | 0% | N/A |
#5 | $0.5M | 15 | 0% | $17.3M |